HeyJaredMeg Rochford
- Indexed articles, last 90 days
- 10
- Latest publication
- Sep 16, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Jul 13, 2026
Latest articles
BNT324-01: Pumitamig Plus Elfe-D Associated with 92% ORR in First Line for Small Cell Lung Cancer (opens the original)
Read excerpt
The combination of pumitamig and elfetabart drozuntecan (elfe-d) induced “encouraging” early efficacy with a manageable safety profile across all lines of therapy and dose levels for patients with small cell lung cancer (SCLC), according to findings presented at the 2026 World Conference on Lung Cancer. BNT324-01 (NCT06892548) is a global phase 1b/2 study that, as noted by the researchers, is the first study evaluating the combination of a PD-L1 x VEGF-A bispecific antibody (bsAb) with an antibo
TAISHAN-302: Tambotatug Pelitecan Improves OS, PFS as Second-Line Treatment for Relapsed SCLC (opens the original)
Read excerpt
A phase 3 study found that tambotatug pelitecan (tam-peli), showed statistically significant improvements in overall survival (OS), progression free survival (PFS), and overall response rate (ORR) compared with topotecan for patients with relapsed small-cell lung cancer (SCLC) regardless of baseline metastasis status or chemotherapy-free interval (CFTI).1 Li Zhang, PhD, with Sun Yat-sen University Cancer Center in Guangzhou, China, presented the results at the 2026 World Conference on Lung Cance
FDA Roundup: Oncology Drug Approvals in 2026 (opens the original)
Read excerpt
This article was updated on September 11, 2026. In August, the US Food and Drug Administration (FDA) approved 6 treatments for a range of cancers, including vusolimogene oderparepvec-wtpg (Tudriqev), iberdomide (Zenbexus), zanidatamab-hrii (Ziihera), daraxonrasib (Rasonque), rusfertide (Mimrylo), and ropeginterferon alfa-2b-njft (Besremi). Tudriqev (vusolimogene oderparepvec-wtpg) On August 6, the FDA approved Tudriqev, in combination with nivolumab, for the treatment of adults with unresectable
Clinicians Cite Financial Hardship, “Gatekeeping” as Barriers to Clinical Trial Enrollment in Black and Hispanic Children - Oncology Nurse Advisor (opens the original)
Read excerpt
Pediatric oncology clinicians cite financial hardship and “gatekeeping” as possible barriers to clinical trial enrollment for Black and Hispanic pediatric cancer patients, according to research published in JAMA Network Open. However, although most parents of these children indicated that they experienced household material hardship (HMH), they did not identify this as a barrier to enrolling their children in clinical trials, study researchers reported. Pediatric cancer survival outcomes have si
Clinicians Cite Financial Hardship, “Gatekeeping” as Barriers to Clinical Trial Enrollment in Black and Hispanic Children (opens the original)
Read excerpt
Pediatric oncology clinicians cite financial hardship and “gatekeeping” as possible barriers to clinical trial enrollment for Black and Hispanic pediatric cancer patients, according to research published in JAMA Network Open. However, although most parents of these children indicated that they experienced household material hardship (HMH), they did not identify this as a barrier to enrolling their children in clinical trials, study researchers reported. Pediatric cancer survival outcomes have si
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.